BioSpace News Archive

Alcami Corporation (“Alcami”) today welcomed the recent announcement by Nectero Medical that they have received clearance from the U.S. Food and Drug Administration of their IND application to initiate Phase II/III trial of the Nectero Endovascular Aneurysm Stabilization Treatment (EAST®) System for the treatment of small- to-mid-sized abdominal aortic aneurysms (AAA).

Telesair, Inc., a technology leader in the respiratory industry, announced today that it has received FDA clearance to market its Bonhawa High Flow Oxygen Therapy (HFOT) system, designed to enhance the treatment of patients with respiratory insufficiency.

The Mark Foundation for Cancer Research announced the recipients of its 2023 Endeavor Award program, providing a total of $12M across seven institutions to support teams of scientists tackling a range of urgent challenges in the prevention, diagnosis, and treatment of cancer.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada has granted Market Authorization for the expanded use of PrTRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include children with cystic fibrosis (CF) ages 2 to 5 years who have at least one copy of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

New research from Shady Grove Fertility (SGF), a US Fertility practice, assures fertility patients who have undergone a saline-infused sonogram (SIS) that they can proceed with intrauterine insemination (IUI) in the same cycle and expect comparable pregnancy rates as if they had waited for another cycle.

Fluent BioSciences, a leading life sciences company dedicated to transforming single-cell analysis with innovative, cost-effective, and scalable solutions, announces the launch of the new PIPseq T10 v5.0 Kit.

Rhythm Pharmaceuticals, Inc. announced several data presentations showing that setmelanotide therapy resulted in sustained and deepened weight loss in patients with severe obesity caused by rare MC4R pathway diseases during The Obesity Society’s Annual Meeting at ObesityWeek®.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today highlighted upcoming presentations of two studies demonstrating positive financial impact of INPEFA® (sotagliflozin) at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting, October 16-19, 2023.

NeuroPace, Inc., a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, announced a series of key enhancements to its RNS System, all designed to streamline care.

DuPont announced that its Board of Directors has declared a third quarter dividend of thirty-six cents per share on the outstanding Common Stock of the Company payable on December 15, 2023, to holders of record of said stock at the close of business on November 30, 2023.